As one of the world’s largest contract development and manufacturing organizations (CDMO), Samsung Biologics has played a key role in building a biopharma hub in South Korea. Now, following significant revenue growth and portfolio diversification efforts in 2021, the company plans to expand its global footprint.
While no location for the new facilities has been announced, Samsung Biologics CEO John Rim made the CDMO’s intentions clear…